Sevelamer Carbonate Tablet, Film Coated
Product Images NDC 55111-789

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sevelamer Carbonate (NDC 55111-789). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy's Laboratories Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure2 (Figure 2)

A forest plot depicting mean difference and 95% confidence intervals for various subgroups comparing Sevelamer Carbonate to placebo. The subgroups include screening BSA, baseline serum phosphorus, age, and dialysis status. The horizontal axis ranges from -5 to 5, with markers indicating if data favors Sevelamer Carbonate or placebo.*

FDA Label Image

Carton

Packaging label for Sevelamer Carbonate Tablets, 800 mg, oral film-coated tablets by Dr. Reddy's Laboratories Limited. The unit-dose package contains 100 tablets (25 blisters of 4 tablets each). Label notes that the unit-dose package is not child resistant and includes storage instructions to protect from moisture and keep out of children's reach. The product NDC is 55111-789-11, and it is made in India.*

FDA Label Image

Container (Container)

Label for Sevelamer Carbonate Tablets 800 mg, film-coated oral tablets, containing 270 tablets per container. Label indicates prescription-only use and storage instructions of 20-25°C. Manufactured by Dr. Reddy's Laboratories Limited, India, and distributed by Dr. Reddy's Laboratories Inc., USA. Includes NDC 55111-789-27 and a barcode.*

FDA Label Image

Figure1 (Figure1)

Chemical structure diagram of Sevelamer Carbonate, showing polymeric repeating units with ammonium and bicarbonate groups, consistent with the composition of the active ingredient Sevelamer Carbonate.*

FDA Label Image

Figure3 (Figure3)

A line graph showing the percentage of patients with a reduction in serum phosphorus levels, comparing Sevelamer Hydrochloride and an active control. The x-axis represents the reduction in serum phosphorus (mg/dL) from baseline, indicating worsened increase to improved reduction, while the y-axis shows the percentage of patients with a reduction greater than a given value.*

FDA Label Image

Figure4

A line graph depicting phosphate change from baseline over 52 weeks of study. The x-axis represents study weeks, and the y-axis shows phosphate change values. Two lines compare Sevelamer Hydrochloride and an active control, with data points shown for each week.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.